Background and aims
Many regions have reported increases in invasive group A streptococcal disease (iGAS) following the waning of the global COVID-19 pandemic, including Australia,1 the UK2 and Europe.3 NZ has longstanding high rates of streptococcal disease.4,5 Starship Children’s Hospital in Auckland has the sole Paediatric Intensive Care Unit (PICU) and paediatric ECMO facility in NZ. We aimed to describe the contemporary profile and outcomes of children with severe iGAS at Starship Hospital.
Methods
Prospective surveillance Jan 2023 – Jan 2025. Children with iGAS admitted to PICU, along with those undergoing surgical procedures and those with intracranial infections, were included.
Results
We identified 51 children, of whom 35 were admitted to PICU. Median age was 4 years. Empyema was the most common focus (23 cases). Other presentations included meningitis (8), osteoarticular infection (8), mastoiditis (3) and necrotising fasciitis (5). Median PICU length of stay was 7 days (IQR 5-20 days). PICU management included ECMO (8), renal dialysis (9), vasopressors (23). There was one death. Six children underwent amputations or major reconstructive surgery due to necrotising fasciitis (2) or purpura fulminans (4).
Conclusion
iGAS is a leading cause of PICU admission for community-onset sepsis at Starship Hospital. We identified several cases of purpura fulminans and meningitis, which are uncommonly reported in iGAS literature. Molecular characterisation of isolates is underway and will be reported. Severe paediatric disease and adverse outcomes highlight the need to address evidence gaps regarding iGAS management and to include children in future clinical trials.